Archer Aviation vs. Rocket Lab: Which Aerospace Stock Is a Better Buy in 2026?

Rocket Lab is presented as the stronger 2026 aerospace investment, with FY2025 revenue of $601.8 million, up 38%, and a $2 billion-plus backlog, versus Archer Aviation's roughly $300,000 of revenue and $618.2 million net loss. Rocket Lab's $198.2 million loss and negative $321.8 million free cash flow remain material, but its losses are narrowing as it expands launch and spacecraft operations and pursues the pending Iridium acquisition. Archer has substantial liquidity and low leverage, but faces FAA-certification, manufacturing-scale, and cash-burn risks, with negative $511.7 million free cash flow and commercial operations still years away.

Analysis

The relevant distinction is not “space versus eVTOL,” but whether incremental capital converts into contracted, repeatable gross profit before the next financing cycle. RKLB has a credible path to higher-value spacecraft systems and launch-adjacent content, but its valuation leaves little room for Neutron schedule slippage, launch anomalies, or acquisition dilution. Any purported IRDM transaction should be independently verified before it is incorporated into estimates; a deal of that scale would materially alter leverage, equity issuance risk, and the investment case.

ACHR remains principally an option on certification plus production execution, not a conventional aerospace earnings story. The low debt load is less meaningful than the cash-burn runway: without independently validated certification timing, unit economics, and firm deposits, announced aircraft commitments should receive limited revenue-credit. The second-order pressure falls on JOBY as well: a certification or manufacturing setback at either company would likely compress the entire eVTOL peer group, while STLA's exposure is strategically useful but not sufficient to underwrite commercial-scale demand.

Over the next 1-3 months, RKLB can outperform on contract awards, successful Electron cadence, and evidence that Neutron capex remains within budget; the catalyst path is operational rather than narrative-driven. Over 6-18 months, the key risk is that launch capacity becomes commoditized while fixed-cost absorption lags, forcing another capital raise at an elevated valuation. Contrarian view: the market may be underpricing the correlation between RKLB's multiple and broader long-duration/AI-capex risk appetite; even strong execution may not protect the stock if real yields rise or speculative-growth liquidity contracts.

Key Decisions for Investors

• Maintain a watch-only stance on ACHR until FAA certification milestones, cash runway, and binding customer deposits are independently disclosed; avoid treating conditional orders as backlog. A certification-delay disclosure or quarterly cash burn above plan would be a downside catalyst for ACHR and likely JOBY within days.
• For aerospace-growth exposure, prefer a defined-risk RKLB position only after verifying the reported IRDM transaction terms and updated pro forma guidance. Use a 3-6 month entry window around quarterly results; reduce if Neutron schedule slips, Electron reliability deteriorates, or forward gross-margin guidance weakens.
• Consider a relative-value basket rather than outright eVTOL beta: long STLA versus short a small ACHR/JOBY basket over 6-12 months. STLA retains optionality from aviation partnerships while its valuation is supported by an established automotive cash-flow base; cover the short leg if certification timing becomes firm and funded production orders convert to deposits.
• Set an event alert for UAL: any conversion of aircraft commitments into material non-refundable deposits would improve the credibility of ACHR demand and invalidate a purely pre-commercial valuation discount. Absent that evidence, do not chase eVTOL rallies driven by partnership headlines.